← Back to All US Stocks

AHCO Stock Analysis - AdaptHealth Corp. AI Rating

AHCO Nasdaq Services-Home Health Care Services DE CIK: 0001725255
Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31
AI Rating
SELL
78% Confidence

Investment Thesis

AdaptHealth demonstrates deteriorating profitability with negative net income of -$70.8M and a concerning net margin of -2.2%, indicating the company is unprofitable despite $3.2B in revenue. The company faces severe financial stress with an interest coverage ratio of 0.9x (unable to cover interest from operating income), high leverage at 1.14x debt-to-equity, and weak liquidity with a current ratio of only 1.02x. While operating cash flow of $601.8M and free cash flow of $219.4M provide some operational relief, the underlying business fundamentals show deteriorating returns (negative ROE and ROA) that suggest structural profitability challenges.

AHCO Strengths

  • + Positive operating cash flow of $601.8M demonstrates cash generation capability from core operations
  • + Free cash flow of $219.4M after capital expenditures provides buffer for debt service and strategic flexibility
  • + Moderate capital intensity with CapEx at 11.9% of revenue suggests efficient asset utilization

AHCO Risks

  • ! Net loss of $70.8M with negative 2.2% net margin indicates fundamental unprofitability and margin compression
  • ! Interest coverage of 0.9x is dangerously low - operating income insufficient to cover interest expense, signaling distress
  • ! High leverage (1.14x debt-to-equity) combined with $1.7B long-term debt and deteriorating profitability creates debt sustainability concerns
  • ! Weak liquidity with current ratio of 1.02x and quick ratio of 0.81x limits financial flexibility
  • ! Declining ROE (-4.7%) and ROA (-1.6%) indicate deteriorating returns on shareholder and asset capital
  • ! Revenue essentially flat YoY (-0.5%) with no organic growth offset

Key Metrics to Watch

AHCO Financial Metrics

Revenue
$3.2B
Net Income
$-70.8M
EPS (Diluted)
$-0.52
Free Cash Flow
$219.4M
Total Assets
$4.3B
Cash Position
$106.1M

AHCO Profitability Ratios

Gross Margin N/A
Operating Margin 2.8%
Net Margin -2.2%
ROE -4.7%
ROA -1.6%
FCF Margin 6.8%

AHCO Balance Sheet & Liquidity

Current Ratio
1.02x
Quick Ratio
0.81x
Debt/Equity
1.14x
Debt/Assets
64.6%
Interest Coverage
0.88x
Long-term Debt
$1.7B

AHCO 5-Year Financial Trend

AHCO 5-year financial data: Year 2021: Revenue $2.5B, Net Income -$21.3M, EPS $-0.95. Year 2022: Revenue $3.0B, Net Income -$161.6M, EPS $-3.08. Year 2023: Revenue $3.2B, Net Income $156.2M, EPS $0.67. Year 2024: Revenue $3.3B, Net Income $69.3M, EPS $0.33. Year 2025: Revenue $3.3B, Net Income -$678.9M, EPS $-5.31.
Revenue
Net Income
EPS (right axis)

5-Year Trend Summary: AdaptHealth Corp.'s revenue has grown significantly by 33% over the 5-year period, indicating strong business expansion. The most recent EPS of $-5.31 indicates the company is currently unprofitable.

AHCO Growth Metrics (YoY)

Revenue Growth
N/A
Year-over-year
Net Income Growth
N/A
Year-over-year
EPS Growth
N/A
Earnings per share
FCF Margin
6.8%
Free cash flow / Revenue

AHCO Quarterly Performance

Quarterly financial performance data for AdaptHealth Corp. including revenue, net income, and earnings per share.
Quarter Revenue Net Income EPS
Q3 2025 $805.9M $22.9M $0.15
Q2 2025 $800.4M $7.5M $0.05
Q1 2025 $777.9M -$2.1M $-0.02
Q3 2024 $804.0M $22.9M $0.15
Q2 2024 $793.3M $14.0M $0.03
Q1 2024 $744.6M -$2.1M $-0.02
Q3 2023 $756.5M $16.1M $0.11
Q2 2023 $727.6M $14.0M $0.03

Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.

AHCO Capital Allocation

Operating Cash Flow
$601.8M
Cash generated from operations
Capital Expenditures
$382.4M
Investment in assets
Dividends
None
No dividend program

AHCO SEC Filings

Access official SEC EDGAR filings for AdaptHealth Corp. (CIK: 0001725255)

Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings. It does not include stock price data and should not be considered financial advice. All fundamental data is sourced from SEC public domain filings. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR | Analysis Date: Mar 19, 2026 | Data as of: 2025-12-31 | Powered by Claude AI